Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice

V Darsalia, A Olverling, M Larsson, S Mansouri… - Regulatory peptides, 2014 - Elsevier
Abstract Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type
2 diabetes (T2D) based on their main property to enhance endogenous glucagon-like …
被引用次数：31 相关文章

[引用][C] Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice

V Darsalia, A Olverling, M Larsson, S Mansouri… - Regulatory …, 2014 - swepub.kb.se
SwePub - Linagliptin enhances neural s... ↓ Direkt till sidans innehåll ↓ Direkt till sidans
sekundära innehåll (sidomenyn) SwePub Om SwePub In English Sökhistorik/mina poster …

Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice

V Darsalia, A Olverling, M Larsson… - Regulatory …, 2014 - pubmed.ncbi.nlm.nih.gov
Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type 2
diabetes (T2D) based on their main property to enhance endogenous glucagon-like peptide …

Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice

V Darsalia, A Olverling, M Larsson, S Mansouri… - Regulatory …, 2014 - infona.pl
Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type 2
diabetes (T2D) based on their main property to enhance endogenous glucagon-like peptide …

Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.

V Darsalia, A Olverling, M Larsson, S Mansouri… - Regulatory …, 2014 - europepmc.org
Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type 2
diabetes (T2D) based on their main property to enhance endogenous glucagon-like peptide …